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Parkinson’s disease (PD) is one of the major neurodegenerative disorders. Mitochondrial malfunction is implicated in
PD pathogenesis. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced putative kinase 1
(PINK1), a serine/threonine kinase, plays an important role in the quality control of mitochondria and more than 70
PINK1 mutations have been identified to cause early-onset PD. However, the regulation of PINK1 gene expression
remains elusive. In the present study, we identified the transcription start site (TSS) of the human PINK1 gene using
switching mechanism at 5’end of RNA transcription (SMART RACE) assay. The TSS is located at 91 bp upstream of
the translation start site ATG. The region with 104 bp was identified as the minimal promoter region by deletion
analysis followed by dual luciferase assay. Four functional cis-acting nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB)-binding sites within the PINK1 promoter were identified. NFκB overexpression led to the
up-regulation of PINK1 expression in both HEK293 cells and SH-SY5Y cells. Consistently, lipopolysaccharide (LPS), a
strong activator of NFκB, significantly increased PINK1 expression in SH-SY5Y cells. Taken together, our results clearly
suggested that PINK1 expression is tightly regulated at its transcription level and NFκB is a positive regulator for
PINK1 expression.
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Parkinson’s disease (PD) is the second most common neu-
rodegenerative disease [1]. PD patients commonly suffer
from muscular dysfunction which resulted in body rigidity,
tremors, bradykinesia, posture instability, and Parkinsonian
gait. Secondary symptoms such as anxiety, depression, me-
mory loss, and dementia may appear over the course of
disease progression [2,3]. The pathological hallmarks of
PD include neurodegeneration of dopaminergic neurons
specifically in the substantia nigra [3], and intracellular ag-
gregation of misfolded proteins forming lewy bodies [4].
Although clinical and experimental studies suggest the
involvement of protein misfolding, oxidative stress and
mitochondrial dysfunction, the fundamental cause of the
disease, its underlying mechanism remains elusive.* Correspondence: weihong@mail.ubc.ca
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unless otherwise stated.Phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN)-induced putative kinase 1 (PINK1), ini-
tially was identified as a downstream molecule of PTEN
in cancer cells [5]. PINK1 is a type I transmembrane
protein of 581 amino acids with a putative serine/threo-
nine kinase domain and an N-terminal mitochondrial
targeting signal. Upon synthesis, the full-length PINK1
(FL-PINK1) is imported into mitochondria with the C-
terminus facing the cytosol and undergoes proteolysis to
produce a predominant product of ~55 kDa (Δ1-PINK1)
and a minor one of ~45 kDa (Δ2-PINK1) [6,7]. The pro-
teolytic process is mediated by matrix processing pep-
tidase and presenilin-associated rhomboid-like protein
(PARL) [8]. Δ1-PINK1 was reported to be released to
the cytosol and interacts with Parkin, a PD-associated
E3 ubiquitin ligase [9]. The binding of Δ1-PINK1 with
Parkin impairs the recruitment of Parkin to mitochondria
and leads to the degradation of Parkin and PINK1 by pro-
teasome pathway in healthy mitochondria [9]. Parkin,
PINK1 and DJ-1 formed a complex to promote ubi-
quitination and degradation of Parkin substrates, in-
cluding Parkin itself and Synphilin-1 [10]. However, intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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membrane potential and mitochondrial oxidative stress,
full-length PINK1 is aggregated on the mitochondrial
membrane and recruits Parkin to mitochondria through
the phosphorylation of Parkin, resulting in mitochon-
drial autophagy. PINK1 deficiency reduces mitochon-
drial membrane potential and compromises complex I
activity of the mitochondria respiratory chain [11]. Studies
suggest that PINK1 together with Parkin is critical for the
quality control of mitochondria, including mitochondrial
integrity, turnover, and functions. More than 70 mutations
in the PINK1 gene were identified in familial PD in
an autosomal recessive manner [12,13]. Most of these
mutations fail to phosphorylate and recruit Parkin to
mitochondria, leading to the accumulation of dysfunc-
tional mitochondria and eventually neuronal death. This
strongly suggests that PINK1 plays a critical role in PD
pathogenesis and dysregulation of PINK1 may contribute
to the development of PD.
Nuclear factor kappa-light-chain-enhancer of activated
B cells (NFκB) is a family of diametric transcription
factors, regulating numerous genes involving in cell sur-
vival, inflammation and immunity. The NFκB family
consists of five members, p50, p52, p65 (RelA), RelB and
C-Rel. All of them share an N-terminal Rel homology
domain (RHD) responsible for DNA binding and homo-
or hetero-dimerization. Only three members including
p65, RelB and C-Rel contain transcription activation do-
main (TAD) necessary for the activation of target genes.
NFκB exists in forms of homo- or hetero-dimer and the
most abundant form is the p65/p50 heterodimer. NFκB
dimers bind with inhibitor of κB (IκB) proteins in cyto-
plasm, preventing its nuclear translocation and DNA
binding. Once IκB protein degradation is induced, NFκB
dimers are released from IκB-NFκB complex and subse-
quently translocated from cytoplasm to nucleus [14],
thus transcription regulation of its target genes is ini-
tialized [15]. NFκB can be activated by stimuli such as
oxidative stress, cytokines, free radicals and biological
antigens. Oxidative stress or free radicals has been shown
to be involved in PD. An increase of NFκB translocation
to the nucleus and activation have been observed in dopa-
minergic neurons from both PD animal models and pa-
tient samples as well as other neurodegenerative disorders
[16-21]. It has been shown that NFκB plays an important
role in regulating PD related genes, such as UCHL1 [22],
USP24 [23] and RNF11 [24].
Although the function of PINK1 is well studied in
terms of mitochondrial quality control, the regulation of
PINK1 gene expression is barely explored. In the present
study, we aimed to understand the transcriptional re-
gulation of the PINK1 gene. For the first time, we iden-
tified that the transcription start site (TSS) of PINK1
is located 91 bp upstream of the translation start site(ATG). The region of 104 bp (−78 to +26) contains the
minimal promoter with functional transcriptional activity
for the PINK1 gene. Furthermore, we showed that the
PINK1 gene promoter contains 4 functional cis-acting
NFκB-binding sites, which promote PINK1 expression.
Taken together, our results demonstrated that PINK1 ex-
pression is tightly regulated at its transcriptional level and
that NFκB is a positive regulator for PINK1 expression.
Results and discussion
Cloning the human PINK1 gene promoter and mapping
its transcription initiation site
The human PINK1 gene spans a region of 18,056 bp on
chromosome 1p36. The human PINK1 gene transcript
(NCBI Reference Sequence: NM_032409) is 2680-bp long
and composed of 8 exons (Figure 1A). Human genomic
DNA samples were extracted from SH-SY5Y cells and
an 1825 bp 5’ flanking region of the PINK1 gene was
amplified and cloned. The DNA fragment was sequenced
(Figure 1B). To identify the transcription start site of hu-
man PINK1 gene, SMART-RACE was performed. The
5’ends of PINK1 cDNA with approximate 650 bp in length
were amplified (Figure 1C). The sequencing results indi-
cated that the transcription start site (TSS), an adenine la-
beled as +1, is located 91 bp upstream of the translation
start site (Figure 1D). Further sequence analysis and a
computer-based transcription factor binding site search
using Genomatix and TFSearch revealed that the hu-
man PINK1 gene has a complex transcriptional unit.
The human PINK1 gene promoter lacks typical TATA
and CAAT boxes, but contains several putative regulatory
elements, such as AP1, MEF, and cAMP-responsive ele-
ments (Figure 1B).
Functional characterization of the PINK1 promoter
To determine the functional promoter region of PINK1
gene, we sub-cloned the 1,825 bp of 5’ flanking region of
the PINK1 gene into the promoterless plasmid vector
pGL3-basic. The pGL3-basic vector lacks eukaryotic pro-
moter and enhancer sequences upstream of a reporter lu-
ciferase gene. The luciferase activity in cells transfected
with this plasmid depends on the presence and proper
orientation of a functional promoter upstream of the lucif-
erase gene. The pPINK1-A plasmid was constructed to
contain the 1,825 bp fragment from −1799 to +26 bp of
PINK1 gene upstream of the luciferase reporter gene.
Plasmid DNA was transfected into HEK293 cells, and lu-
ciferase activity was measured by a luminometer to reflect
promoter activity. Compared with cells transfected with
an empty vector pGL3-basic, pPINK1-A-transfected cells
showed a robust luciferase activity (113.47 ± 10.63 RLU)
(Figure 2B). This result indicated that the 1,825 bp
fragment contains the functional promoter region of
the human PINK1 gene. To further identify the minimal
Figure 1 Sequence features of the human PINK1 gene promoter. (A) The genomic organization of human PINK1 gene on chromosome
1. E represents exon. ATG is the translation start codon and TGA is the stop codon. (B) The nucleotide sequence of the human PINK1 gene
from −1799 to +97 bp. The adenine +1 represents the transcription start site. The putative transcription factor binding sites are underlined in
bold face. (C) SMARTer-RACE was performed to map the PINK1 transcription start site. The PCR product was run on a 1.5% agarose gel. (D) The
PCR product was cloned into pcDNA4 vector and sequenced to identify the transcription start site. The first base after the adapter is the TSS from
which is underlined.
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series of deletion mutants within the 1,825 bp fragment of
pPINK1-A were generated as indicated in Figure 2A. The
luciferase activity assays of these deletion mutants were
performed. The results indicated that placing the 1,825 bpfragment in a reverse orientation (pPINK1-B) com-
pletely abolished luciferase activities observed in pPINK1-
A transfected cells (Figure 2B). Deletion of −1799 to -
103 bp in pPINK1-F reduced the luciferase activities of
pPINK1-A moderately (71.16 ± 3.02 RLU). Deletion of the
Figure 2 Deletion analysis of the human PINK1 gene promoter. (A) Schematic diagram of the PINK1 promoter constructs consisting of the
5’ flanking region with serial deletions cloned into the pGL3-basic vector. Arrow shows the direction of transcription. The numbers represents the
end points of each construct. (B) The deletion plasmids were cotransfected with pCMV-Luc into HEK293 cells. 24 h after the transfection, the
luciferase activity was measured and expressed in relative luciferase units (RLU). The pCMV-Luc was used to normalize for transfection efficiency.
The values represent means ± SEM. n = 3, *p < 0.0001, by one-way ANOVA followed by post hoc Tukey’s multiple comparisons test.
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pPINK1-F occluded the remaining luciferase activities
(Figure 2B). Further deletion of the promoter region
to −78 to +26 bp maintained similar luciferase activity
in pPINK1-G (78.44 ± 4.74 RLU) comparing to pPINK1-F
(p > 0.05). However, additional deletion of 31 bp from
pPINK1-G to pPINK1-H (−47 to +26) significantly
reduced the luciferase activity to 11.46 ± 2.50 RLU
(p < 0.05). These data suggest that the region from −78
to +26, containing the transcription start site, possesses
the minimal promoter activity.
The human PINK1 gene promoter contains NFκB
binding sites
Computer-based transcription factor binding site ana-
lysis revealed four putative NFκB elements in the 1.8 kb
promoter region of the human PINK1 gene (Figure 1B).
To determine whether NFκB signaling regulates PINK1
gene transcription by interacting with these putative
NFκB cis-acting elements, the effect of NFκB overex-
pression on the promoter activity of the 1.8 kb region
were examined. Plasmid pPINK1-A, containing 4 NFκB
binding sites, was transfected into HEK293 cells, SH-
SY5Y cells or N2A cells with either the NFκB expression
plasmid or the empty vector pMTF. The results showed
that NFκB overexpression significantly increased PINK1
promoter activity to 3.43 ± 0.55 folds (Figure 3A), 2.11 ±
0.10 folds (Figure 3B) and 1.63 ± 0.01 folds (Figure 3C)in HEK293, SH-SY5Y cells and N2A cells, respectively
(p < 0.01). These results suggest that NFκB activates
PINK1 gene transcription and the PINK1 promoter
fragment contains functional NFκB sites.
The four putative NFκB elements in the 1.8-kb PINK1
promoter region are located at −1493 to -1474 bp, −814
to -794 bp, −111 to -92 bp, and −54 to -35 bp, respect-
ively. The sequences of these regions are highly homolo-
gous to the NFκB consensus sequence 5’-GGGRNNYYCC
in which R stands for purine, Y stands for pyrimidine, and
N stands for deoxynucleotides. To determine which puta-
tive binding site actually binds with NFκB, EMSA was per-
formed using four pairs of synthesized oligonucleotides
containing the binding sequence. The sequences of these
four oligonucleotides are: PINK1-NFκB-1, 5’- caaatgg-
gaaattcatctat, PINK1-NFκB-2, 5’- ggcatggggatccaccatctt,
PINK1-NFκB-3, 5’- gcaaagggaaagtcactgct, and PINK1-
NFκB-4, 5’- agtcggggaactgccgcggg, respectively. A NFκB
binding probe (NFκB-Wt-oligo) served as a positive
binding probe and a mutant NFκB binding probe
(NFκB-Mu-oligo) which loses the NFκB binding ability
served as a negative binding probe [25]. NFκB-Wt-oligo
was labelled with IRDye-700 and the labelled probe was
named NFκBwt-IR700. After 30-min incubation with
NFκB enriched nuclear extracts of HEK293 cells, the
NFκBwt-IR700 bound to NFκB protein and formed a
shifted DNA-protein complex band (Figure 3D, lane2).
Adding 10-fold of the unlabelled NFκB-Wt-oligo sharply
Figure 3 NFκB binds to human PINK1 gene promoter. The effects of NFκB on the human PINK1 promoter in HEK293 cells (A), SH-SY5Y cells
(B) and N2A cells (C) were analyzed by luciferase reporter assays. The PINK1 promoter reporter plasmid (pPINK1-A) or pGL3-promoter was
co-transfected into cells with NFκB expression plasmid or the empty vector pMTF. Values indicate means ± SEM. n = 3, *p < 0.01 by Student’s
t-test.(D) EMSA with NFκB p65 consensus probe. Lane 1 is labeled probe alone without protein extract. Incubation of the probe with NFκB p65
enriched nuclear extracts forms a shifted DNA-protein complex band (lane 2). Competition assays were performed by further adding different
competition oligonucleotides including NFκB-mu, NFκB-wt, and PINK1-NFκB. (E) EMSA with PINK1 NFκB-1 probe. Lane1 is labelled IR700-PINK1-
NFκB-1 probe only. Addition of NFκB p65 enriched nuclear extracts forms a shifted DNA-protein complex band (lane 2). Lane3 to 6, the
competitor NFκB-wt and NFκB-mu were added at 10- or 100-fold. Lane 7 and 8, addition of anti-p65 antibody forms a super shifted DNA-protein-
antibody band (lane7) and NFκB-wt was added for competition (lane 8).
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the unlabelled NFκB-Wt-oligo competed with and re-
duced the binding of NFκB-wt-IR700 to NFκB protein
(Figure 3D, lane 5). Increasing the amount of unlabelled
NFκB-Wt-oligo to 100-fold almost completely abolished
the shifted band (Figure 3D, lane 6). Addition of the
NFκB-Mu-oligo, which fails to bind with NFκB, did not
affect the interaction between NFκBwt-IR700 and protein
(Figure 3D, lane 3–4). The PINK-NFκB-1 to −4 oligos
were tested for their ability to compete against NFκBwt-
IR700 binding with NFκB protein. The results indicated
that addition of 30-fold excess of the four PINK1-NFκB
oligos individually barely reduced the intensity of the
shifted band (Figure 3D, lane 7, 9, 11, 13). However, in-
creasing the amount to 300-fold significantly reduced the
intensity of the shifted band for PINK1-NFκB-1 and
PINK1-NFκB-3, with PINK1-NFκB-1 being a stronger
competitor than PINK1-NFκB-3 in binding with NFκB
protein (Figure 3D, lane 8 and 12). PINK1-NFκB-2 and
PINK1-NFκB-4 showed limited ability in competingwith NFκBwt-IR700 to bind with NFκB (Figure 3D,
lane 10 and 14).
To further confirm the binding between PINK1-NFκB-1
in the human PINK1 promoter region and NFκB, we per-
formed EMSA with IRDye-700 labelled PINK1-NFκB-1.
The probe showed a shifted band (Figure 3E lane 2) after
incubation with nuclear extracts from HEK293 cells over-
expressing NFκB. The intensity of the shifted band was
remarkably reduced when a 10-fold excess of NFκB-Wt-
oligo was added to the incubation and abolished after the
concentration of the competitor increased to 100-fold
(Figure 3E, lane3-4). However, no competition was found
when either 10-fold or 100-fold NFκB-Mu-oligo was ad-
ded (Figure 3E, lane 5 and 6). A super-shift assay was
further performed with the anti-p65 antibody. The super-
shifted band containing labelled PINK1-NFκB-1, NFκB,
and anti-p65 antibody was observed at the top of the gel
(Figure 3E, lane 7), and the band was competed down
by NFκB-Wt-oligo (Figure 3E lane 8). Taken together,
the EMSA results demonstrate that NFκB binds to the
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of PINK1 promoter region is the main binding site.NFκB increases the human PINK1 gene expression
Next we examined the effects of NFκB on PINK1 gene
expression by RT-PCR and Western blot analysis. The
semi-quantitative RT-PCR was performed to test whe-
ther endogenous PINK1 mRNA level was affected by
NFκB. Using the human β-actin as an internal control,
NFκB overexpression significantly increased endogenous
human PINK1 transcription by 59.51% ± 15.13% (p < 0.01)
(Figure 4A). To examine whether NFκB modulates PINK1
expression at the protein level, endogenous PINK1 protein
was detected by Western blot analysis. The full-length
human PINK1 protein (FL-PINK1, 63 kDa) and its pro-
teolytic products, Δ1-PINK1 (55 kDa) and Δ2-PINK1
(45 kDa), were detected and analyzed. The endogenous
PINK1 expression increased by 114.53% ± 38% (p < 0.01)
(Figure 4B) in the NFκB overexpressing HEK293 cells
when compared with the vector control. Meanwhile, the
same experiment was performed in SH-SY5Y cells and
three PINK1 species were observed. Consistently, the
endogenous PINK1 bands were also up-regulated in
NFκB overexpressing SH-SY5Y cells by 45.26% ± 19.58%,Figure 4 NFκB upregulates human PINK1 gene expression. (A) NFκB in
transfected with either the NFκB expression vector or empty vector pMTF.
PINK1 coding sequence or the human β-actin coding sequence. (B) NFκB i
transfected with NFκB were harvested 48 h after transfection for protein de
collected by Licor. A significant increase of endogenous PINK1 was observe
increased by NFκB in SH-SY5Y cells. SH-SY5Y cells were transfected with NF
protein detections. The human PINK1 protein and its proteolysis products Δ
as the internal control. (D) LPS treatment facilitated PINK1 expression in SH
subjected to Western blot. The human β-actin level was served as a contro
means ± SEM. n = 3, *p <0.01 by Student’s t-test.41.10 ± 6.70% and 48.54 ± 4.50% (p < 0.01), respectively
(Figure 4C). Furthermore, when the NFκB activator LPS
(Lipopolysaccharide) was used to treat SH-SY5Y cells for
16 hours, endogenous PINK1 protein levels were elevated
compared to the untreated control by 26.77% ± 2.33%,
24.46 ± 2.59% and 83.57 ± 4.60% (p < 0.001) (Figure 4D),
respectively.
Mitochondrial dysfunction plays a critical role in the
development of PD and other neurodegenerative dis-
eases such as Alzheimer’s disease [26-29] and multiple
sclerosis [30,31]. Mutations in several genes including
UCHL1 [32], LRRK2 [33], PINK1 [12,34], PARKIN [35]
are associated with PD pathogenesis. PINK1 is a mito-
chondrial targeted protein and has been extensively stu-
died because of its crucial role in autosomal recessive
familial Parkinson’s disease [36] and protective role against
mitochondrial dysfunction, oxidative stress and apoptosis
[37,38]. However, the regulation of PINK1 gene expression
has not been well addressed yet [39]. For the first time,
we studied the transcriptional regulation of the human
PINK1 gene in the present study.
To investigate the transcription and translation of the
human PINK1 gene, we first mapped the adenine 91 bp
upstream of the first ATG in exon 1 as the transcription
start site. Next we cloned the 1.8 kb fragment of 5’ UTRcreases the endogenous human PINK1 mRNA level. HEK293 cells were
RT-PCRs were performed using either primers specific to the human
ncreases the endogenous human PINK1 protein levels. HEK293 cells
tection. Cell lysates were run on 10% glycine gel and images were
d. (C) The endogenous human PINK1 protein level was dramatically
κB p65 plasmids or the control vector pMTF and then harvested for
1-PINK1 (55kD) and Δ2-PINK1 (45kD) were all increased. β-actin acted
-SY5Y cells. Cells were harvested after being treated for 16 h and then
l. Quantification was performed by Image J software. Values indicate
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stream of a reporter luciferase gene. The luciferase assay
showed that this 1.8 kb fragment has strong promoter
activity, indicating that the 1.8 kb fragment functions as
the human PINK1 gene promoter. Subsequently, by dele-
tion analysis we found that the 104 bp fragment from −78
to 26 serves as the minimal promoter region. The human
PINK1 gene promoter does not have high GC content
(<50%) like the human BACE1 and TMP21 promoter
[40,41]. Computer-based analysis revealed that the human
PINK1 promoter contains several putative transcriptional
factor binding elements such as MZF1, AP1F, CREB,
NFκB and EGRF. Due to the importance of NFκB in PD,
the potential regulation of PINK1 by NFκB was examined.
There are four putative NFκB binding sites in the human
PINK1 gene promoter and our results indicate that two of
them physically bind with NFκB p65 with one strong
binding site at the distal end. The effect of NFκB p65 on
human PINK1 gene promoter was further confirmed by
luciferase assay, where the overexpression of NFκB p65
elevated PINK1 promoter activity dramatically. Further-
more, we examined the effects of overexpression of NFκB
p65 on PINK1 expression at the transcription and transla-
tion levels. Indeed, NFκB p65 increased the human PINK1
expression significantly at both the mRNA and protein
levels. Due to the low expression level of the human
PINK1 gene, few commercially available antibodies could
detect the endogenous PINK1 clearly. We therefore
cloned the human PINK1 plasmid, encoding a full-length
PINK1 protein (~63 kDa) that is proteolytically processed
into at least two shorter forms (~55 kDa and ~45 kDa),
into a human dopaminergic neuroblastoma cell line (SH-
SY5Y) [6,7,42]. In this cell line, we were able to detect
three PINK1-related bands. Only the full-length PINK1
could be detected in the HEK293 cell line. This might be
due to different expression levels and mitochondrial func-
tion between the different cell lines.
In this study, we clearly showed that NFκB significant
upregulates PINK1 expression in both human and ro-
dent cell lines, indicating that same regulation pathway
exists in both human and rodents. It provides the strong
evidence to support the use of rodent models to study
the regulation of PINK1 expression in vivo, promoting
the investigation of PD pathogenesis and drug develop-
ment. Moreover, as SH-SY5Y cells are human dopamin-
ergic cells and the dopaminergic neurons are mainly
affected in PD patients, the results from SH-SY5Y cells
can better represent the possible PINK1 regulation path-
way in the brain of PD patients.
N-terminal proteolysis of FL-PINK1 produces two frag-
ments, Δ1-PINK1 and Δ2-PINK1. After processing the
proteolysis productions translocate to cytosol and undergo
proteasome degradation [6,7,42]. Although the functional
role of PINK1 in mitochondria or in Parkinson’s diseasehas not been well defined, PINK1 has been shown to con-
fer a protective effect through preventing mitochondrial
dysfunction, anti-apoptosis and promoting cell survival
[43]. It has also been reported that FL-PINK1 accumulates
in the brains of patients with sporadic PD or other synu-
cleinopathies, and interestingly, the cleavage products of
PINK1 are also increased in PD brains [44-46]. This accu-
mulation of Δ-PINK1 might due to the upregulation of
PINK1 expression in response to PD-related stress [44].
Given that truncated PINK1 can confer protection, in-
creased cleavage of PINK1 may play a role in protecting
neurons during PD pathogenesis. Our result showed that
all of the three forms of PINK1 (FL-PINK1, Δ1-PINK1
and Δ2-PINK1) were elevated by overexpression or activa-
tion of NFκB signaling. Thus, the increase of PINK1 ex-
pression by NFκB activation could be neuroprotective. On
the other hand, previous studies have suggested that the
elevation of NFκB in dopaminergic neurons of PD patients
is a reflection of the apoptotic and inflammatory state of
the diseased brain [16]. These studies suggest that the ac-
tivation of NFκB could be a double-edged sword in PD
pathogenesis and the role of NFκB dysregulation in PD
warrants further study.Conclusion
Our results demonstrate that PINK1 expression is tightly
regulated at its transcription level and NFκB signaling is
a positive regulator for PINK1 gene expression.Methods
Primers and plasmid construction
To amplify the 5’-untranslated region of the PINK1 gene
from DNA extracted from the human neuroblastoma
cells SH-SY5Y, a forward primer (5’-cgcgagctcgttgcccag
gctggtcttg) corresponding to −1799 bp of the transcrip-
tional start site on exon 1 and a reverse primer (5’-ccc
aagcttcacaacaaacttggggcggtgcc) corresponding to +26 bp
of the transcriptional start site were used. The PINK1
DNA fragment was cloned into a pGL3-basic vector up-
stream of a luciferase reporter gene (Promega) to con-
struct pPINK1-A. Primers were designed to include
restriction enzyme sites so that the PCR-amplified frag-
ments can be inserted into the multiple cloning sites of
the pGL3-basic vector. A series of deletion mutations
(pPINK1-B, pPINK1-C, pPINK1-D, pPINK1-E, pPINK1-F,
pPINK1-G, pPINK1-H and pPINK1-I) of PINK1 promoter
were constructed utilizing primers listed as following:
26 F-cccaagcttcacaacaaacttggggcggtgcc, and 1799R- cccaa
gcttgttgcccaggctggtcttg; −795 F -ggcatggggatccaccatcttg,
and -339 F-ccgctcgaggacctcgaatgctgccc; −103 F-ccgctcg
agaaagtcactgctagaggc, and -50R-cccaagcttcgactcggcgcgt
ggggg; −78 F-ccgctcgagccagcatagcgcccccac, and -47 F
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gcgcctgcgcctgcg, respectively.Switching mechanism at 5’end of RNA transcription
(SMART) RACE cDNA amplification
Total RNA was extracted from SH-SY5Y cells using TRI
reagent (Sigma) following the manufacturer’s protocol.
SMART-RACE was performed using the SMARTer™
RACE cDNA Amplification Kit (Clontech) following the
user’s manual. Simply, the first stand cDNA was syn-
thesized from total RNA extracted from SH-SYHY cells
with oligo (dT) primer in the presence of SMARTer IIA
oligonucleotide (5’-aagcagtggtatcaacgcagagtacxxxxx (X is
undisclosed base in the proprietary SMARTer oligo se-
quence). The SMARTer IIA oligonucleotide is able to
anneal to the 5’-end of the first stand cDNA and serve
as template to extend the 5’-end cDNA tail. A PINK1 re-
verse primer (5’-ccgaagcttgccctgcaagcgtctcgtgt) was spe-
cifically designed to recognize the +431 to +450 bp of
human PINK1 gene downstream of the translation start
site (ATG). The PCR products containing PINK1pro-
moter region were amplified using SMARTer IIA oligo-
nucleotide and PINK1 reverse primer and the first stand
cDNA as template. The resulting PCR products were
cloned into pcDNA4/myc-His A vector for sequencing
and the first nucleotide linking with the adapter se-
quence was identified as the transcription start site of
the human PINK1 gene.Cell culture, transfection, and luciferase assay
Human embryonic kidney HEK293, mouse neuroblast-
oma N2A and human neuroblastoma SH-SY5Y cell lines
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal bovine serum (FBS), 1 mM
sodium pyruvate, 2 mM L-glutamine, 50 units/ml pe-
nicillin G sodium, and 50 μg/ml streptomycin sulfate
(Invitrogen). All cells were maintained in a humidified
37°C incubator containing 5% CO2. 500 ng plasmid DNA
per well of 24-well-plate for luciferase assay or 2 μg plas-
mid DNA per 35-mm-diameter plate for RNA extraction
and Western blot analysis were used for cell transfection,
respectively. For luciferase assay, pCMV-Rluc (Promega,
USA) was co-transfected as a control to normalize
the transfection efficiency. The cells were transfected
using PEI reagent (Cat#. 23966, Polysciences Inc.) or
Lipofectamine-™ 2000 reagent (Invitrogen). Cells were
harvested 24 hrs after transfection and lysed with 100 μl
1× passive lysis buffer (Promega) per well. Firefly luci-
ferase activities and Renilla luciferase activities of the
same sample were sequentially assayed on a lumin-
ometer (Turner Designs Model 20/20) following the
protocol of the Dual-luciferase Reporter Assay System
(Promega). The firefly luciferase activity was normalizedto the Renilla luciferase activity and the resulted value
reflected the promoter activity.
Electrophoretic mobility shift assay (EMSA)
HEK293 cells were transiently transfected with NFκB
p65 and nuclear extracts were collected. Cells were rinsed
and harvested with 1 × phosphate-buffered saline. After
centrifugation, cell pellets were resuspended with 5 × vol-
ume of buffer A [10 mM HEPES pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol
(DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF)].
Cells were pipetted up and down gently and maintained
on ice for 15 minutes. The cell suspension was transferred
to a Kontes all glass Dounce tissue grinder and ruptured
by 10 strokes. 10% NP40 was added into the cell suspen-
sion for a final concentration of 0.5%. The samples were
placed on ice for 15 minutes and stroked 5 more times.
Crude nuclei were collected by centrifugation at 2000 g
for 10 minutes and washed three times with buffer A con-
taining 0.5% NP40 and resuspended in buffer C [20 mM
HEPES pH 7.9, 0.4 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl
fluoride (PMSF), 10% Glycerol] at 4°C for 15 min. The
samples were centrifuged at 12000 g for 4 min at 4°C, and
the supernatant containing nuclear proteins was collected.
EMSA was performed as previously described [40]. Four
pairs of oligonucleotides containing the putative NFκB
binding site on human PINK1 promoter region were syn-
thesized for detecting the binding ability of NFκB to
PINK1 promoter. The sequences of the oligos were listed
as following: NFκB-54-35, forward, agtcggggaactgccgcggg
and reverse, cccgcggcagttccccgact; NFκB-111-92, forward,
gcaaagggaaagtcactgct and reverse, agcagtgactttccctttgc;
NFκB-814-794, forward, ggcatggggatccaccatctt and reverse
aagatggtggatccccatgcc; NFκB-1493-1474, forward, caaatg
ggaaattcatctat and reverse atagatgaatttcccatttg. The probes
were labeled with IRDye-700 (IDT). Prior to incubation
with nuclear extract, oligonucleotide probes were heated
at 98°C for 5 minutes and annealed at 65°C for 10 minutes.
0.5 pmol of annealed probes were incubated with 2 μl of
nuclear extract for 20 minutes at 22°C and the reaction
mixtures were separated on a 4% Tris-glycine-EDTA gel
in darkness. The mobility of probes on the gel was visual-
ized using the LI-COR Odyssey (LI-COR Biosciences). For
the competition assay, wild-type NFκB consensus oligonu-
cleotides (forward: agttgaggggactttcccaggc, and reverse:
gcctgggaaagtcccctcaact) and mutant NFκB consensus oli-
gonucleotides (forward: agttgaggccactttcccaggc, and re-
verse: gcctgggaaagtggcctcaact) were used as positive and
negative controls, respectively. For the super shift assay,
the nuclear extract was incubated in 10 × EMSA binding
buffer (100 mM Tris, 500 mM KCl, 10 mM dithiothreitol,
pH 7.5) with monoclonal anti-NFκBp65 antibody (Sigma)
for 10 minutes prior to the probe adding.
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HEK293 cells and SH-SY5Y cells transfected with NFκB
p65 were harvested 48 hours after the transfection and
total RNA was extracted using TRI reagent (Sigma).
Reverse transcription was sequentially performed using
ThermoScript™ RT-PCR system kit following the manufac-
turer’s protocol (Invitrogen). The PINK1 gene specific
primer PINK1 776 F-taccagtgcaccaggagaag and PINK1
984R- gcttgggacctctcttggat were used to amplify a 208 bp
fragment of human PINK1 gene. The β-actin gene was
also amplified using the forward primer (hActin-
662fBamHI: cgaggatccggacttcgagcaagagatgg) and reverse
primer (hActin-1124rXbaI: cagtctagagaagcatttgcggtggacg),
which produced a 500 bp fragment. The PCR products
were analyzed on 2% agarose gels.
Western blot analysis
Western blot was performed as described previously
[47,48]. NFκB p65 plasmid DNAs (2 μg/35 mm dish)
were transfected into HEK293 cells and SH-SY5Y cells.
48 hours after transfection, cells were harvested by
RIPA-DOC buffer (1% Triton X-100, 0.1% sodium dode-
cylsulphate, 1% sodium deoxycholate, 0.15 mM NaCl,
0.05 M Tris–HCl pH 7.2, 0.5 mM phenylmethylsulfonyl
fluoride) containing protease inhibitors (Roche). Cell ly-
sates were separated on 10% Tris-glycine gel and pro-
teins were transferred onto PVDF membrane, followed
by primary antibody incubation overnight at 4°C. The
primary antibodies were rabbit anti-PINK1 polyclonal
antibody (1:500 dilution, Novus BC100-494), anti-p65
(1:1000 dilution, Cell Signaling), monoclonal anti-NFκB
p65 antibody (1:1000 dilution, Sigma), and anti-β-actin
antibody AC-15 (1:100, 000 dilution, Sigma). The pro-
tein bands were visualized using the LI-COR Odyssey
(LI-COR Biosciences) after secondary antibody (goat
anti-mouse, goat anti-rabbit, LI-COR Biosciences) label-
ing. The resulted protein bands were quantified by Image
J software. The experiment was done in triplicate to
minimize experimental errors.
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